Connect with us
[the_ad id="89560"]

Health

RFK Jr. appoints Robert Malone, Martin Kulldorff, other COVID shot critics to overhauled CDC vaccine panel

Published

11 minute read

From LifeSiteNews

By Robert Jones

Health and Human Services Secretary Robert F. Kennedy Jr. has announced eight appointments for the CDC’s top vaccine advisory panel, following his dismissal of all 17 previous members, citing a need to rebuild public trust in the federal immunization process.

RFK Jr. said the new Advisory Committee on Immunization Practices (ACIP) will demand “definitive safety and efficacy data” before issuing any new vaccine recommendations and will re-evaluate existing guidance. The restructured panel is set to convene on June 25.

The appointees include several prominent physicians and scientists, including former Harvard epidemiologist Martin Kulldorff and mRNA researcher Robert Malone, both known for their criticism of COVID-19-era public health policy and the COVID-19 shots.

Kulldorff helped draft the Great Barrington Declaration with Jay Bhattacharya and Sunetra Gupta, which called for focused protection rather than mass lockdowns – a position widely debated among epidemiologists. He also spoke out strongly against vaccine passports and mandates, as well as mask mandates and contact tracing. He was dismissed from Harvard in 2024 because of his refusal to receive the COVID-19 injections.

Malone, who conducted early work on mRNA vaccine delivery systems, was banned from several platforms for posts deemed “misleading” during the COVID crisis. He has given related interviews on The Joe Rogan Experience and elsewhere and was reinstated on X following Elon Musk’s revision of COVID-19 policies.

Retsef Levi, a professor at MIT, has raised concerns about potential cardiovascular risks linked to COVID-19 mRNA shots and has called for stricter safety monitoring. In 2023, a petition circulated opposing his work, though it did not gain traction.

Other appointees include:

  • Joseph Hibbeln, an NIH psychiatrist and nutrition researcher focused on immune and neurodevelopmental health.
  • Cody Meissner, a pediatric infectious disease expert with previous experience on both FDA and CDC vaccine panels.
  • James Pagano, a veteran emergency physician with decades of clinical experience.
  • Vicky Pebsworth, a nurse-scientist with prior FDA vaccine advisory roles and Pacific Region Director of the National Association of Catholic Nurses. She is also a Lay Dominican.
  • Michael Ross, an OB-GYN and clinical researcher with a background in immunology and women’s health policy.

Joseph R. Hibbeln, MD, is a psychiatrist and neuroscientist with a career in clinical research, public health policy, and federal service. As former Acting Chief of the Section on Nutritional Neurosciences at the National Institutes of Health, he led research on immune regulation, neurodevelopment, and mental health. His work has informed U.S. public health guidelines, particularly in maternal and child health. With more than 120 peer-reviewed publications and extensive experience in federal advisory roles, Dr. Hibbeln brings expertise in immune-related outcomes, psychiatric conditions, and evidence-based public health strategies.

Martin Kulldorff, MD, PhD, is a biostatistician and epidemiologist formerly at Harvard Medical School and a leading expert in vaccine safety and infectious disease surveillance. He has served on the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee and the CDC’s Vaccine Safety Subgroup of the Advisory Committee on Immunization Practices, where he contributed to national vaccine safety monitoring systems. Dr. Kulldorff developed widely used tools such as SaTScan and TreeScan for detecting disease outbreaks and vaccine adverse events. His expertise includes statistical methods for public health surveillance, immunization safety, and infectious disease epidemiology. He has also been an influential voice in public health policy, advocating for evidence-based approaches to pandemic response.

Retsef Levi, PhD, is the Professor of Operations Management at the MIT Sloan School of Management and a leading expert in healthcare analytics, risk management, and vaccine safety. He has served as Faculty Director of MIT Sloan’s Food Supply Chain Analytics and Sensing Initiative and co-led the Leaders for Global Operations Program. Dr. Levi has collaborated with public health agencies to evaluate vaccine safety, including co-authoring studies on mRNA COVID-19 vaccines and their association with cardiovascular risks. His research has contributed to discussions on vaccine manufacturing processes, safety surveillance, and public health policy. Dr. Levi has also served on advisory committees and engaged in policy discussions concerning vaccine safety and efficacy. His expertise spans healthcare systems optimization, epidemiologic modeling, and the application of AI and data science in public health. Dr. Levi’s work continues to inform national and international debates on immunization safety and health system resilience.

Robert W. Malone, MD, is a physician-scientist and biochemist known for his early contributions to mRNA vaccine technology. He conducted foundational research in the late 1980s on lipid-mediated mRNA delivery, which laid the groundwork for later developments in mRNA-based therapeutics. Dr. Malone has held academic positions at institutions including the University of California, Davis, and the University of Maryland, and has served in advisory roles for the U.S. Department of Health and Human Services and the Department of Defense. His expertise spans molecular biology, immunology, and vaccine development.

Cody Meissner, MD, is a Professor of Pediatrics at the Geisel School of Medicine at Dartmouth and a nationally recognized expert in pediatric infectious diseases and vaccine policy. He has served as Section Chief of Pediatric Infectious Disease at Dartmouth-Hitchcock Medical Center and has held advisory roles with both the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). Dr. Meissner has been a voting member of the CDC’s Advisory Committee on Immunization Practices and the FDA’s Vaccines and Related Biological Products Advisory Committee, where he has contributed to national immunization guidelines and regulatory decisions. His expertise spans vaccine development, immunization safety, and pediatric infectious disease epidemiology. Dr. Meissner has also been a contributing author to American Academy of Pediatrics policy statements and immunization schedules, helping shape national standards for pediatric care.

James Pagano, MD, is a board-certified Emergency Medicine physician with over 40 years of clinical experience following his residency at UCLA. He has worked in diverse emergency settings, from Level 1 trauma centers to small community hospitals, caring for patients across all age groups, including infants, pregnant women, and the elderly. Dr. Pagono served on multiple hospital committees, including utilization review, critical care, and medical executive boards. He is strong advocate for evidence-based medicine.

Vicky Pebsworth, OP, PhD, RN, earned a doctorate in public health and nursing from the University of Michigan. She has worked in the healthcare field for more than 45 years, serving in various capacities, including critical care nurse, healthcare administrator, health policy analyst, and research scientist with a focus on public health policy, bioethics, and vaccine safety. She is the Pacific Region Director of the National Association of Catholic Nurses. She is a former member of the Food and Drug Administration’s Vaccine and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee’s 2009 H1N1 Vaccine Safety Risk Assessment Working Group and Vaccine Safety Working Group (Epidemiology and Implementation Subcommittees).

Michael A. Ross, MD, is a Clinical Professor of Obstetrics and Gynecology at George Washington University and Virginia Commonwealth University, with a career spanning clinical medicine, research, and public health policy. He has served on the CDC’s Advisory Committee for the Prevention of Breast and Cervical Cancer, where he contributed to national strategies for cancer prevention and early detection, including those involving HPV immunization. With research experience in hormone therapies, antibiotic trials, and immune-related conditions such as breast cancer prevention, Dr. Ross has engaged in clinical investigations with immunologic relevance. He has advised major professional organizations, including the American College of Obstetricians and Gynecologists, and contributed to federal advocacy efforts around women’s health and preventive care. His continued service on biotech and healthcare boards reflects his commitment to advancing innovation in immunology, reproductive medicine, and public health.

Kennedy framed the move as part of a broader campaign to remove conflicts of interest and restore credibility to federal vaccine recommendations. Just a few days ago, he accused the panel of having been “little more than a rubber stamp for any vaccine” and pledged that the new members would not have direct ties with the vaccine industry.

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

More from this author

Business

Prime minister can make good on campaign promise by reforming Canada Health Act

Published on

From the Fraser Institute

By Nadeem Esmail

While running for the job of leading the country, Prime Minister Carney promised to defend the Canada Health Act (CHA) and build a health-care system Canadians can be proud of. Unfortunately, to have any hope of accomplishing the latter promise, he must break the former and reform the CHA.

As long as Ottawa upholds and maintains the CHA in its current form, Canadians will not have a timely, accessible and high-quality universal health-care system they can be proud of.

Consider for a moment the remarkably poor state of health care in Canada today. According to international comparisons of universal health-care systems, Canadians endure some of the lowest access to physicians, medical technologies and hospital beds in the developed world, and wait in queues for health care that routinely rank among the longest in the developed world. This is all happening despite Canadians paying for one of the developed world’s most expensive universal-access health-care systems.

None of this is new. Canada’s poor ranking in the availability of services—despite high spending—reaches back at least two decades. And wait times for health care have nearly tripled since the early 1990s. Back then, in 1993, Canadians could expect to wait 9.3 weeks for medical treatment after GP referral compared to 30 weeks in 2024.

But fortunately, we can find the solutions to our health-care woes in other countries such as Germany, Switzerland, the Netherlands and Australia, which all provide more timely access to quality universal care. Every one of these countries requires patient cost-sharing for physician and hospital services, and allows private competition in the delivery of universally accessible services with money following patients to hospitals and surgical clinics. And all these countries allow private purchases of health care, as this reduces the burden on the publicly-funded system and creates a valuable pressure valve for it.

And this brings us back to the CHA, which contains the federal government’s requirements for provincial policymaking. To receive their full federal cash transfers for health care from Ottawa (totalling nearly $55 billion in 2025/26) provinces must abide by CHA rules and regulations.

And therein lies the rub—the CHA expressly disallows requiring patients to share the cost of treatment while the CHA’s often vaguely defined terms and conditions have been used by federal governments to discourage a larger role for the private sector in the delivery of health-care services.

Clearly, it’s time for Ottawa’s approach to reflect a more contemporary understanding of how to structure a truly world-class universal health-care system.

Prime Minister Carney can begin by learning from the federal government’s own welfare reforms in the 1990s, which reduced federal transfers and allowed provinces more flexibility with policymaking. The resulting period of provincial policy innovation reduced welfare dependency and government spending on social assistance (i.e. savings for taxpayers). When Ottawa stepped back and allowed the provinces to vary policy to their unique circumstances, Canadians got improved outcomes for fewer dollars.

We need that same approach for health care today, and it begins with the federal government reforming the CHA to expressly allow provinces the ability to explore alternate policy approaches, while maintaining the foundational principles of universality.

Next, the Carney government should either hold cash transfers for health care constant (in nominal terms), reduce them or eliminate them entirely with a concordant reduction in federal taxes. By reducing (or eliminating) the pool of cash tied to the strings of the CHA, provinces would have greater freedom to pursue reform policies they consider to be in the best interests of their residents without federal intervention.

After more than four decades of effectively mandating failing health policy, it’s high time to remove ambiguity and minimize uncertainty—and the potential for politically motivated interpretations—in the CHA. If Prime Minister Carney wants Canadians to finally have a world-class health-care system then can be proud of, he should allow the provinces to choose their own set of universal health-care policies. The first step is to fix, rather than defend, the 40-year-old legislation holding the provinces back.

Continue Reading

COVID-19

FDA requires new warning on mRNA COVID shots due to heart damage in young men

Published on

From LifeSiteNews

By Doug Mainwaring

Pfizer and Moderna’s mRNA COVID shots must now include warnings that they cause ‘extremely high risk’ of heart inflammation and irreversible damage in males up to age 24.

The Trump administration’s Food and Drug Administration (FDA) announced it will now require updated safety warnings on mRNA COVID-19 shots to include the “extremely high risk” of myocarditis/pericarditis and the likelihood of  long-term, irreversible heart damage for teen boys and young men up to age 24.

The required safety updates apply to Comirnaty, the mRNA COVID shot manufactured by Pfizer Inc., and Spikevax, the mRNA COVID shot manufactured ModernaTX, Inc.

According to a press release, the FDA now requires each of those manufacturers to update the warning about the risks of myocarditis and pericarditis to include information about:

  1. the estimated unadjusted incidence of myocarditis and/or pericarditis following administration of the 2023-2024 Formula of mRNA COVID-19 shots and
  2. the results of a study that collected information on cardiac magnetic resonance imaging (cardiac MRI) in people who developed myocarditis after receiving an mRNA COVID-19 injection.

The FDA has also required the manufacturers to describe the new safety information in the adverse reactions section of the prescribing information and in the information for recipients and caregivers.

Additionally, the fact sheets for healthcare providers and for recipients and caregivers for Moderna COVID-19 shot and Pfizer-BioNTech COVID-19 shot, which are authorized for emergency use in individuals 6 months through 11 years of age, have also been updated to include the new safety information in alignment with the Comirnaty and Spikevax prescribing information and information for recipients and caregivers.

In a video published on social media, Dr. Vinay Prasad, director of the Center for Biologics Evaluation & Research Chief Medical and Scientific Officer, explained the alarming reasons for the warning updates.

While heart problems arose in approximately 8 out of 1 million persons ages 6 months to 64 years following reception of the cited shots, that number more than triples to 27 per million for males ages 12 to 24.

Prasad noted that multiple studies have arrived at similar findings.

Continue Reading

Trending

X